Max Healthcare Institute Ltd Q3 FY2026 Concall Summary

Key Takeaways

• One-off disruptions masked underlying momentum: Revenue and EBITDA dipped sequentially as a temporary insurance stalemate shifted the payor mix toward institutional patients, while CGHS drug-pricing rules forced the discontinuation of select high-value oncology drugs. Both disruptions have since been resolved or are normalizing.
• Insurance contracts reset with a structural fix: After a disruptive tariff standoff with four stand-alone health insurers, Max secured a price increase and put in place an automatic renewal mechanism, removing the risk of a repeat stalemate in the next cycle.
• Capacity engine is running hot and margin-accretive: New facilities at Nanavati and Saket are already delivering 39% and 30% margins on partial bed counts, with breakeven described as almost immediate. The network is on track to add ~1,200 beds including the Gurgaon greenfield, with total beds expected to hit 8,000 by FY28.
• CGHS rate revision provides a tailwind, but the full lift is still to come: The net sustained benefit from CGHS/ECHS price increases is INR 140 crore after netting off the onco drug and GST impacts, yet ECHS revised prices only in December and some PSUs are still seeking budget approvals to match CGHS rates.
• What to watch next quarter: The pace of institutional-patient distillation at Dwarka as occupancy tightens ahead of the expansion, the commissioning timeline for Max Smart’s 200 beds, and whether the full CGHS/ECHS price increase flows through to revenue.

One-Off Headwinds: Insurance Disruption & Oncology Drug Discontinuation

• Insurance stalemate shifted the payor mix: A tariff dispute with four stand-alone health insurers disrupted cashless services, temporarily pushing the institutional patient share to 36% and compressing margins. The stalemate was fully resolved toward the end of the quarter with a price increase secured.
• Structural fix now in place: An automatic contract renewal mechanism has been agreed with the four insurers, so the disruption should not recur in the next cycle. Complaints against some insurers rose over 40% during the quarter, which management believes taught all parties a lesson.
• Oncology drug discontinuation was a margin-neutral revenue headwind: CGHS pricing guidelines required a 30% discount on chemotherapy drugs. Where Max’s purchase margin was already below 30%, supply was discontinued. These were high-value but low-margin drugs used for institutional patients, so the impact was on revenue, not profitability.
• CGHS/ECHS rate revision nets to INR 140 crore of sustained benefit: The gross benefit of the CGHS price increase is INR 200 crore, offset by INR 80 crore from the onco drug discontinuation and INR 60 crore from the GST rate reduction on drugs and consumables. The full price increase has not yet flowed through, as ECHS revised prices only in December and some PSUs are still seeking budget approvals.

Abhay Soi: "This is something that does not make sense because these are branded drugs and if your margins are already, say less than 20%, and you are being asked to supply them at a 30% discount to MRP, then obviously, nobody is going to supply and we are going to have a problem."

Capacity Expansion: The Accretive Growth Flywheel

• New facilities are margin-accretive from the start: Nanavati and Saket are already operating at 39% and 30% EBITDA margins respectively on only 60–70 beds each. Management attributes this to operating leverage: breakeven is almost immediate and margins expand as more beds are added.
• Max Smart ready to commission, awaiting occupancy certificate: Infrastructure for ~200 beds, operation theaters and OPDs is complete. The occupancy certificate is expected by end of February 2025, with the original timeline having been FY28, so the project is ahead of schedule.
• Dwarka expansion triggered by faster-than-expected ramp: The hospital is already at 75% occupancy with 20% margins despite 50% institutional business. The Board approved adding 260 beds to take total capacity to 560 beds. Construction will take at least two years, during which occupancy is expected to tighten to 85%, naturally distilling the payor mix toward higher-margin cash and insurance patients.
• Gurgaon greenfield on track for H1 FY27: The first phase is expected to commission toward the end of H1 FY27. Management is willing to accept a deeper initial loss if it means securing clinicians on day one, prioritizing speed of ramp over near-term profitability.
• Pipeline extends through FY29: Max Lucknow is expanding to ~500 beds by end-FY26; Nagpur civil work has started with a 24-month timeline; a 450-bed Pune hospital is planned by 2030; Patparganj is now expected by FY29.

Abhay Soi: "Because of the operating leverage, you do not have any suppression of margins. In fact, the breakeven is almost immediate and is accretive very quickly."

Payor Mix & Pricing Dynamics

• Institutional share rose temporarily to 36%: The insurance disruption drove the shift, but management expects this to normalize as cashless services are fully restored and as new brownfield beds ramp up. Higher institutional business is typical in the early stages of new capacity, then distills over time.
• Medical inflation is very low single digits, apples-to-apples: ARPOB growth has historically been 8–9%, but that includes 25% oncology growth, 40% robotics growth, and international patient growth. Backing those out, real medical cost inflation is minimal. Additionally, 30% of billing is for drugs at MRP, so inflation applies only to 70% of the bill.
• Doctor team departure was a swap, not a loss: A large team departed to a peer, but Max simultaneously hired a very large team from that same peer. Management characterized it as an effective swap with no net capacity loss.

Abhay Soi: "By the end of the day, and I keep saying this, that medical inflation is in very low single digits. If your ARPOB growth has only been 8% or 9 historically, which has included growth in oncology by around 25%, growth in robotics by around 40%, growth in international patients, etc. and you actually back it all off, what is the real growth in medical cost, apples-to-apples?"

Profitability: Margin Walk & Capital Allocation

• Q3 margin compression was multi-factorial: The sequential EBITDA margin decline was driven by the payor mix shift toward institutional patients, pre-commissioning expenses for brownfield beds, and the GST rate change on drugs and consumables. Seasonality also played a role, as the prior year had a strong vector-borne disease season that did not repeat.
• Pre-commissioning costs are real but hard to isolate: Staff such as housekeeping, nurses and front-end personnel are overstaffed in existing facilities and training before moving to new ones. Clinician costs are largely the same, so the true pre-commissioning burden is embedded and difficult to dissect.
• ROCE, not EBITDA per bed, is the North Star: Management explicitly does not chase EBITDA per bed or ARPOB accretion as targets. A lower EBITDA per bed is acceptable if capital is deployed efficiently to generate strong ROCE. This philosophy underpins the willingness to take institutional business in new facilities initially.
• Jaypee Hospital turnaround progressing: Revenue is up 30–35% YoY after an initial post-acquisition dip when referrals were stopped. Margins are now 3–4% below the overall network margin, and the trajectory is improving.

Abhay Soi: "We may have a lower EBITDA per bed, but you have to focus on ROCE over there. I mean we are not focusing on making EBITDA per bed or ARPOB accretive or whatever. We are focusing on ROCE."

Balance Sheet & Capex

• FY26 capex target is up to INR 1,900 crore: Capex is typically back-ended, and work done does not always align with capex recognition in tandem. Management considers the numbers conservative and will revisit them at end-March 2025, potentially floating new figures for FY27.
• Net debt to rise modestly, staying below 1x: Net debt is expected to increase by INR 500–600 crore but will remain under 1x unless an M&A opportunity arises. Incremental beds coming on stream are all EBITDA and margin-accretive, so better cash flows are expected to follow.
• GRAP-related delays were contained: Construction delays from GRAP restrictions amounted to 3–4 months collectively. No project has been pushed out by more than six months from its original timeline; three-year projects will take an additional four to five months.

Guidance & Commitments

Key Metrics